Dendritic cell immunotherapy

Annals of the New York Academy of Sciences

Volumn 1284, Issue 1, 2013, Pages 31-45

  Sabado, Rachel Lubong ^a   Bhardwaj, Nina ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Dendritic cells; Immunotherapy; Vaccine

Indexed keywords

DENDRITIC CELL VACCINE; IPILIMUMAB; TICILIMUMAB;

ARTICLE; CELL MATURATION; CYTOLOGY; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; IMMUNOTHERAPY; MELANOMA; METASTATIC MELANOMA; TUMOR MICROENVIRONMENT;

EID: 84877355954     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12125     Document Type: Article

References (204)

1. Banchereau, J. et al. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18: 767-811.
2. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3: 133-146.
3. Vignali, D.A. & V.K. Kuchroo 2012. IL-12 family cytokines: immunological playmakers. Nat. Immunol. 13: 722-728.
4. McKenna, K., A.S. Beignon & N. Bhardwaj 2005. Plasmacytoid dendritic cells: linking innate and adaptive immunity. J. Virol. 79: 17-27.
5. Tel, J. et al. 2012. Harnessing human plasmacytoid dendritic cells as professional APCs. Cancer Immunol. Immunother. 61: 1279-1288.
6. Salio, M. et al. 2003. Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur. J. Immunol. 33: 1052-1062.
7. Dunn, G. P. et al. 2005. A critical function for type I interferons in cancer immunoediting. Nat. Immunol. 6: 722-729.
8. Hartmann, E. et al. 2003. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res. 63: 6478-6487.
9. Gerlini, G. et al. 2007. Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clin. Immunol. 125: 184-193.
10. Battaglia, A. et al. 2009. Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. Cancer Immunol. Immunother. 58: 1363-1373.
11. Sharma, M.D. et al. 2007. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2, 3-dioxygenase. J. Clin, Invest. 117: 2570-2582.
12. Munn, D.H. et al. 2004. Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114: 280-290.
13. Guermonprez, P. et al. 2002. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20: 621-667.
14. Joffre, O.P. et al. 2012. Cross-presentation by dendritic cells. Nature reviews. Immunology 12: 557-569.
15. Cambi, A., M. Koopman & C.G. Figdor 2005. How C-type lectins detect pathogens. Cell Microbiol. 7: 481-488.
16. van Vliet, S.J., J.J. Garcia-Vallejo & Y. van Kooyk 2008. Dendritic cells and C-type lectin receptors: coupling innate to adaptive immune responses. Immunol. Cell Biol. 86: 580-587.
17. Redelinghuys, P. & G.D. Brown 2011. Inhibitory C-type lectin receptors in myeloid cells. Immunol, Lett. 136: 1-12.
18. Akira, S. & K. Takeda 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4: 499-511.
19. Kato, H. et al. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441: 101-105.
20. Pedra, J.H., S.L. Cassel & F.S. Sutterwala 2009. Sensing pathogens and danger signals by the inflammasome. Curr. Opin. Immunol. 21: 10-16.
21. Skoberne, M., A.S. Beignon & N. Bhardwaj 2004. Danger signals: a time and space continuum. Trends Mol. Med. 10: 251-257.
22. Jego, G. et al. 2005. Dendritic cells control B cell growth and differentiation. Curr. Dir. Autoimmun. 8: 124-139.
23. Munz, C. et al. 2005. Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood 105: 266-273.
24. Fujii, S. et al. 2002. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat. Immunol. 3: 867-874.
25. Skoberne, M. et al. 2005. Apoptotic cells at the crossroads of tolerance and immunity. Curr. Top. Microbiol. Immunol. 289: 259-292.
26. Cools, N. et al. 2007. Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J. Leukoc. Biol. 82: 1365-1374.
27. Mellor, A.L. & D.H. Munn 2004. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4: 762-774.
28. Munn, D.H. & A.L. Mellor 2004. IDO and tolerance to tumors. Trends Mol. Med. 10: 15-18.
29. + Tr cells. Blood 105: 1162-1169.
30. Jonuleit, H. et al. 2000. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192: 1213-1222.
31. Woo, E.Y. et al. 2001. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61: 4766-4772.
32. Liyanage, U.K. et al. 2002. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169: 2756-2761.
33. + regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol. 9: 239-244.
34. Skoberne, M. et al. 2006. The apoptotic-cell receptor CR3, but not alphavbeta5, is a regulator of human dendritic-cell immunostimulatory function. Blood 108: 947-955.
35. Frleta, D. et al. 2012. HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44. J. Clin. Invest. 122: 4685-4697.
36. Agace, W.W. & E.K. Persson 2012. How vitamin A metabolizing dendritic cells are generated in the gut mucosa. Trends Immunol. 33: 42-48.
37. Satzger, I. et al. 2006. Spontaneous regression of melanoma with distant metastases-report of a patient with brain metastases. Eur. J. Dermatol. 16: 454-455.
38. Wang, R.F. & S.A. Rosenberg 1999. Human tumor antigens for cancer vaccine development. Immunol. Rev. 170: 85-100.
39. Kim, R., M. Emi & K. Tanabe 2007. Cancer immunoediting from immune surveillance to immune escape. Immunology 121: 1-14.
40. Fridman, W.H. et al. 2012. The immune contexture in human tumours: impact on clinical outcome. Nature reviews. Cancer 12: 298-306.
41. Sikora, A.G., Y. Hailemichael & W.W. Overwijk 2012. Conference scene: immune effector mechanisms in tumor immunity. Immunotherapy 4: 141-143.
42. Gandhi, R.T. et al. 2009. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 27: 6088-6094.
43. Palucka, A.K. et al. 2006. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J. Immunother. 29: 545-557.
44. Redman, B.G. et al. 2008. Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. J. Immunother. 31: 591-598.
45. O'Neill, D.W. & N. Bhardwaj 2005. Differentiation of peripheral blood monocytes into dendritic cells. Curr. Protoc. Immunol. Chapter 22: Unit 22F 24.
46. O'Neill, D. & N. Bhardwaj 2005. Generation of autologous peptide- and protein-pulsed dendritic cells for patient-specific immunotherapy. Methods Mol. Med. 109: 97-112.
47. Banchereau, J. et al. 2001. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61: 6451-6458.
48. Klechevsky, E. et al. 2009. Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines. Hum. Immunol. 70: 281-288.
49. Romano, E. et al. 2011. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin. Cancer Res. 17: 1984-1997.
50. Marroquin, C.E. et al. 2002. Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells. J. Immunother. 25: 278-288.
51. Pulendran, B. et al. 2000. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J. Immunol. 165: 566-572.
52. Guimond, M. et al. 2010. In vivo role of Flt3 ligand and dendritic cells in NK cell homeostasis. J. Immunol. 184: 2769-2775.
53. Kantoff, P.W. et al. 2010. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363: 411-422.
54. Small, E.J. et al. 2006. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24: 3089-3094.
55. De Vries, I. J. et al. 2003. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 63: 12-17.
56. Dhodapkar, M.V. et al. 2001. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193: 233-238.
57. Dhodapkar, M.V. & R.M. Steinman 2002. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. Blood 100: 174-177.
58. de Vries, I.J. et al. 2003. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin. Cancer Res. 9: 5091-5100.
59. Lee, A.W. et al. 2002. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 20 (Suppl. 4): A8-A22.
60. Jongmans, W. et al. 2005. Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails. J. Immunother. 28: 480-487.
61. Krause, P. et al. 2007. Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO. J. Leukoc. Biol. 82: 1106-1114.
62. Morelli, A.E. & A.W. Thomson 2003. Dendritic cells under the spell of prostaglandins. Trends Immunol. 24: 108-111.
63. Baratelli, F.E. et al. 2004. Prostaglandin E2-dependent enhancement of tissue inhibitors of metalloproteinases-1 production limits dendritic cell migration through extracellular matrix. J. Immunol. 173: 5458-5466.
64. Scandella, E. et al. 2002. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 100: 1354-1361.
65. Krause, P. et al. 2009. Prostaglandin E(2) enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells. Blood 113: 2451-2460.
66. Kwissa, M. et al. 2012. Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates. Blood 119: 2044-2055.
67. Schnare, M. et al. 2001. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. 2: 947-950.
68. Napolitani, G. et al. 2005. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6: 769-776.
69. Boullart, A.C. et al. 2008. Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol. Immunother. 57: 1589-1597.
70. Mailliard, R.B. et al. 2004. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 64: 5934-5937.
71. Lee, J.J. et al. 2008. Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. J. Leukoc. Biol. 84: 319-325.
72. + T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 29: 330-336.
73. MartIn-Fontecha, A. et al. 2003. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J. Exp. Med. 198: 615-621.
74. Adams, S. et al. 2008. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 181: 776-784.
75. Nair, S. et al. 2003. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J. Immunol. 171: 6275-6282.
76. Melief, C.J. & S.H. van der Burg 2008. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer 8: 351-360.
77. Bijker, M.S. et al. 2008. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur. J. Immunol. 38: 1033-1042.
78. Kenter, G.G. et al. 2008. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin. Cancer Res. 14: 169-177.
79. + T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin. Cancer Res. 14: 178-187.
80. Kenter, G.G. et al. 2009. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361: 1838-1847.
81. de Vos van Steenwijk, P.J. et al. 2012. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol. Immunother. 61: 1485-1492.
82. Leffers, N. et al. 2009. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int. J. Cancer 125: 2104-2113.
83. Sabbatini, P. et al. 2012. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin. Cancer Res. 18: 6497-6508.
84. Zeestraten, E.C. et al. 2013. Addition of interferon-alpha to the p53-SLP(R) vaccine results in increased production of interferon-gamma in vaccinated colorectal cancer patients: a phase I/II clinical trial. Int. J. Cancer 132: 1581-1591.
85. Speetjens, F.M. et al. 2009. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin. Cancer Res. 15: 1086-1095.
86. Rosario, M. et al. 2012. Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. Aids 26: 275-284.
87. Barrou, B. et al. 2004. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol. Immunother. 53: 453-460.
88. Salcedo, M. et al. 2006. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol. Immunother. 55: 819-829.
89. Mahdian, R. et al. 2006. Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHC-restricted antigen-specific antitumor T cells. Med. Oncol. 23: 273-282.
90. Schnurr, M. et al. 2001. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res. 61: 6445-6450.
91. Thumann, P. et al. 2003. Antigen loading of dendritic cells with whole tumor cell preparations. J. Immunol. Methods 277: 1-16.
92. Knutson, K.L. 2002. Technology evaluation: DCVax, Northwest Biotherapeutics. Curr. Opin. Mol. Ther. 4: 403-407.
93. Kandalaft, L.E. et al. 2013. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2: e22664.
94. Schnurr, M. et al. 2005. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 105: 2465-2472.
95. Jenne, L., G. Schuler & A. Steinkasserer 2001. Viral vectors for dendritic cell-based immunotherapy. Trends Immunol. 22: 102-107.
96. Brockstedt, D.G. & T.W. Dubensky 2008. Promises and challenges for the development of Listeria monocytogenes-based immunotherapies. Expert Rev. Vaccines 7: 1069-1084.
97. Bellone, S. et al. 2009. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines. J. Virol. 83: 6779-6789.
98. Carrasco, J. et al. 2008. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J. Immunol. 180: 3585-3593.
99. Butterfield, L.H. et al. 2008. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J. Immunother. 31: 294-309.
100. Veron, P. et al. 2007. Major subsets of human dendritic cells are efficiently transduced by self-complementary adeno-associated virus vectors 1 and 2. J. Virol. 81: 5385-5394.
101. Skoberne, M. et al. 2008. KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity. J. Clin. Invest. 118: 3990-4001.
102. Breckpot, K., J.L. Aerts & K. Thielemans 2007. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther. 14: 847-862.
103. He, Y., D. Munn & L.D. Falo Jr. 2007. Recombinant lentivector as a genetic immunization vehicle for antitumor immunity. Expert Rev. Vaccines. 6: 913-924.
104. Schroers, R. et al. 2000. Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol. Ther. 1: 171-179.
105. Dyall, J. et al. 2001. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood 97: 114-121.
106. Lizee, G., M.I. Gonzales & S.L. Topalian 2004. Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. Hum. Gene Ther. 15: 393-404.
107. Bobadilla, S., N. Sunseri & N.R. Landau 2012. Efficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory protein. Gene Ther.
108. Breckpot, K. et al. 2004. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. J. Immunol. 172: 2232-2237.
109. He, Y. et al. 2005. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J. Immunol. 174: 3808-3817.
110. Dullaers, M. et al. 2006. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther. 13: 630-640.
111. Yang, L. et al. 2008. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat. Biotechnol. 26: 326-334.
112. Nair, S.K. et al. 2002. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann. Surg. 235: 540-549.
113. Muller, M.R. et al. 2004. Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. Blood 103: 1763-1769.
114. Nencioni, A. et al. 2003. Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer. Cancer Gene Ther. 10: 209-214.
115. Milazzo, C. et al. 2003. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 101: 977-982.
116. Gilboa, E. & J. Vieweg 2004. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev. 199: 251-263.
117. Heiser, A. et al. 2001. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res. 61: 3388-3393.
118. Strobel, I. et al. 2000. Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther. 7: 2028-2035.
119. Koido, S. et al. 2000. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J. Immunol. 165: 5713-5719.
120. Heiser, A. et al. 2002. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109: 409-417.
121. Routy, J.P. et al. 2010. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin. Immunol. 134: 140-147.
122. Shortman, K., M.H. Lahoud & I. Caminschi 2009. Improving vaccines by targeting antigens to dendritic cells. Exp. Mol. Med. 41: 61-66.
123. Tacken, P.J., R. Torensma & C.G. Figdor 2006. Targeting antigens to dendritic cells in vivo. Immunobiology 211: 599-608.
124. Jinushi, M., F.S. Hodi & G. Dranoff 2008. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol. Rev. 222: 287-298.
125. Jinushi, M. & H. Tahara 2009. Cytokine gene-mediated immunotherapy: current status and future perspectives. Cancer Sci. 100: 1389-1396.
126. Filipazzi, P. et al. 2007. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25: 2546-2553.
127. Sica, A. & V. Bronte 2007. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117: 1155-1166.
128. Lutz, E. et al. 2011. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation. Ann. Surg. 253: 328-335.
129. Bayne, L.J. et al. 2012. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 21: 822-835.
130. van Kooyk, Y. 2008. C-type lectins on dendritic cells: key modulators for the induction of immune responses. Biochem. Soc. Trans. 36: 1478-1481.
131. Caminschi, I. et al. 2008. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood 112: 3264-3273.
132. + T cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1. J. Immunol. 177: 2276-2284.
133. + T cell responses through targeting of antigen to Dectin-2. Cell Immunol. 239: 87-91.
134. Boscardin, S.B. et al. 2006. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J. Exp. Med. 203: 599-606.
135. Wang, B. et al. 2012. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res. 14: R39.
136. Cheong, C. et al. 2010. Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody. Blood 116: 3828-3838.
137. Idoyaga, J. et al. 2011. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc. Natl. Acad. Sci. US A 108: 2384-2389.
138. Tacken, P.J. et al. 2005. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 106: 1278-1285.
139. Ramakrishna, V. et al. 2004. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J. Immunol. 172: 2845-2852.
140. Trumpfheller, C. et al. 2012. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J. Intern. Med. 271: 183-192.
141. Verdijk, P. et al. 2009. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin. Cancer Res. 15: 2531-2540.
142. Fujiwara, S. et al. 2012. Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer. J. Immunother. 35: 513-521.
143. Lesterhuis, W.J. et al. 2011. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin. Cancer Res. 17: 5725-5735.
144. Aarntzen, E.H. et al. 2013. Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. Clin. Cancer Res. 19: 1525-1533
145. + T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS One 5: e11144.
146. Schadendorf, D. et al. 2006. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann. Oncol. 17: 563-570.
147. Higano, C.S. et al. 2009. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115: 3670-3679.
148. Bennaceur, K. et al. 2008. Dendritic cells dysfunction in tumour environment. Cancer Lett. 272: 186-196.
149. Aptsiauri, N. et al. 2007. Role of altered expression of HLA class I molecules in cancer progression. Adv. Exp. Med. Biol. 601: 123-131.
150. Bronte, V. & S. Mocellin 2009. Suppressive influences in the immune response to cancer. J. Immunother. 32: 1-11.
151. Chang, C.C. et al. 2006. Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells. J. Biol. Chem. 281: 18763-18773.
152. Peggs, K.S. et al. 2009. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 206: 1717-1725.
153. Pardoll, D.M. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nature reviews. Cancer 12: 252-264.
154. Iwai, Y. et al. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 99: 12293-12297.
155. Strome, S.E. et al. 2003. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 63: 6501-6505.
156. Blank, C. et al. 2006. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int. J. Cancer 119: 317-327.
157. Berger, R. et al. 2008. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14: 3044-3051.
158. Brahmer, J.R. et al. 2010. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28: 3167-3175.
159. Topalian, S.L. et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366: 2443-2454.
160. Brahmer, J.R. et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366: 2455-2465.
161. Yuan, J. et al. 2008. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl. Acad. Sci. USA 105: 20410-20415.
162. Hodi, F.S. et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363: 711-723.
163. O'Day, S.J., O. Hamid & W.J. Urba 2007. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 110: 2614-2627.
164. Wang, C. et al. 2009. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol. Rev. 229: 192-215.
165. + T cells. Cancer Res. 62: 3459-3465.
166. Murillo, O. et al. 2009. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur. J. Immunol. 39: 2424-2436.
167. Kocak, E. et al. 2006. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. 66: 7276-7284.
168. Simeone, E. & P.A. Ascierto 2012. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. J. Immunotoxicol. 9: 241-247.
169. Elgueta, R. et al. 2009. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 229: 152-172.
170. Vonderheide, R.H. & M.J. Glennie 2013. Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 19: 1035-1043.
171. Beatty, G.L. et al. 2011. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331: 1612-1616.
172. Kutzler, M.A. et al. 2005. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J. Immunol. 175: 112-123.
173. + T cells. Proc. Natl. Acad. Sci. USA 101: 1969-1974.
174. + T cells for use in adoptive immunotherapy of established tumors. Nat. Med. 12: 335-341.
175. Steel, J.C., T.A. Waldmann & J.C. Morris 2012. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol. Sci. 33: 35-41.
176. Pouw, N. et al. 2010. Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells. Cancer Immunol. Immunother. 59: 921-931.
177. Jakobisiak, M., J. Golab & W. Lasek 2011. Interleukin 15 as a promising candidate for tumor immunotherapy. Cytok. Growth Factor Rev. 22: 99-108.
178. Schluns, K.S. et al. 2000. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat. Immunol. 1: 426-432.
179. + T regulatory cells. J. Immunother. 29: 313-319.
180. Minkis, K. et al. 2008. Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. Cancer Res. 68: 9441-9450.
181. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3: 133-146.
182. Czerniecki, B.J. et al. 2007. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 67: 1842-1852.
183. Rudman, S.M. et al. 2011. A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin. Cancer Res. 17: 1998-2005.
184. Vicari, A.P. et al. 2002. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. 196: 541-549.
185. Fujita, T. et al. 2009. Inhibition of transforming growth factor-beta-mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types. Cancer Res. 69: 5142-5150.
186. Lopez, M.N. et al. 2009. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J. Clin. Oncol. 27: 945-952.
187. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115: 739-746.
188. + Th1 immunity with poly IC as adjuvant. J. Exp. Med. 206: 1589-1602.
189. Warger, T. et al. 2006. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 108: 544-550.
190. Vandepapeliere, P. et al. 2008. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 26: 1375-1386.
191. Baumgaertner, P. et al. 2006. Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens. Cancer Res. 66: 1912-1916.
192. Diefenbach, C.S. et al. 2008. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin. Cancer Res. 14: 2740-2748.
193. Fourcade, J. et al. 2008. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J. Immunother. 31: 781-791.
194. Dhodapkar, M.V. 2009. Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges. Front. Biosci. 14: 796-807.
195. Chang, D.H. et al. 2005. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201: 1503-1517.
196. Marshall, J.L. et al. 2005. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol. 23: 720-731.
197. Marshall, J.L. et al. 2000. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol. 18: 3964-3973.
198. Kaneno, R. et al. 2009. Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J. Transl. Med. 7: 58.
199. Shurin, G.V. et al. 2009. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J. Immunol. 183: 137-144.
200. Aquino, A. et al. 2004. Drug-induced increase of carcinoembryonic antigen expression in cancer cells. Pharmacol. Res. 49: 383-396.
201. Correale, P. et al. 2003. Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int. J. Cancer 104: 437-445.
202. Kikuta, J. & M. Ishii 2012. Recent advances in intravital imaging of dynamic biological systems. J. Pharmacol. Sci. 119: 193-197.
203. Lu, W. et al. 2004. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 10: 1359-1365.
204. Garcia, F. et al. 2013. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci. Transl. Med. 5: 166ra162.